Bellerophon Therapeutics (BLPH) stock price, revenue, and financials

Bellerophon Therapeutics market cap is $42.3 m.
View Company

$42.3 M

BLPH Mkt cap, 29-Jul-2021
Bellerophon Therapeutics Net income (Q1, 2021)-5.5 M
Bellerophon Therapeutics EBIT (Q1, 2021)-5.9 M
Bellerophon Therapeutics Cash, 31-Mar-202139.7 M
Bellerophon Therapeutics EV4.1 M
Get notified regarding key financial metrics and revenue changes at Bellerophon TherapeuticsLearn more
Banner background

Bellerophon Therapeutics Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

R&D expense

33.4m16.7m17.9m20.3m11.0m17.9m

General and administrative expense

14.9m7.1m6.7m7.6m6.4m8.4m

Operating expense total

48.2m23.8m24.6m27.9m17.5m26.3m

EBIT

(46.6m)(23.8m)(24.6m)(27.9m)(17.5m)(26.3m)

Interest income

109.0k95.0k184.0k378.0k397.0k

Pre tax profit

(46.5m)(24.3m)(54.8m)(2.6m)(15.1m)(26.9m)

Income tax expense

(438.0k)(5.4m)(1.8m)(2.1m)

Net Income

(46.5m)(23.8m)(54.8m)2.8m(13.3m)(24.7m)

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

R&D expense

9.5m8.4m7.1m5.1m4.0m2.5m3.3m8.0m4.4m6.4m5.8m5.2m2.3m2.6m3.3m2.2m3.5m6.1m3.6m

General and administrative expense

4.6m3.4m4.3m2.0m1.2m1.7m1.4m3.1m1.7m2.1m2.1m1.6m2.0m1.6m1.3m1.9m2.3m2.2m2.3m

Operating expense total

14.1m11.9m11.4m7.1m5.2m4.2m4.8m11.1m6.2m8.5m7.9m6.8m4.3m4.2m4.6m4.1m5.8m8.3m5.9m

EBIT

(12.9m)(11.6m)(11.2m)(7.1m)(5.2m)(4.2m)(4.8m)(11.1m)(6.2m)(8.5m)(7.9m)(6.8m)(4.3m)(4.2m)(4.6m)(4.1m)(5.8m)(8.3m)(5.9m)

Interest income

19.0k27.0k27.0k30.0k22.0k22.0k27.0k53.0k33.0k99.0k91.0k92.0k130.0k121.0k89.0k34.0k7.0k9.0k

Pre tax profit

(12.9m)(11.6m)(11.1m)(7.1m)(5.1m)(4.2m)(19.1m)(7.6m)(1.3m)(11.5m)11.1m(2.6m)(4.1m)(4.3m)(5.0m)(5.9m)(7.9m)(5.5m)

Income tax expense

(5.4m)(1.8m)(2.1m)

Net Income

(12.9m)(11.6m)(11.1m)(7.1m)(5.1m)(4.2m)(19.1m)(23.1m)(7.6m)4.1m(11.5m)11.1m(795.0k)(4.1m)(4.3m)(5.0m)(3.8m)(7.9m)(5.5m)

Bellerophon Therapeutics Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

6.3m14.5m28.8m16.6m9.9m47.6m

Prepaid Expenses

5.4m3.4m650.0k405.0k420.0k

Current Assets

29.5m26.5m35.6m17.4m10.4m48.1m

PP&E

1.8m1.4m1.0m664.0k316.0k169.0k

Total Assets

38.4m29.7m36.8m18.4m13.1m50.2m

Accounts Payable

1.6m2.8m3.9m2.8m3.1m3.7m

Short-term debt

658.0k704.0k

Current Liabilities

8.1m6.5m7.1m7.5m7.6m10.4m

Long-term debt

1.7m956.0k

Total Debt

2.3m1.7m

Total Liabilities

8.1m11.7m39.4m14.5m9.5m12.0m

Common Stock

131.0k569.0k587.0k46.0k95.0k

Preferred Stock

Additional Paid-in Capital

130.9m142.2m176.2m179.8m193.3m252.6m

Retained Earnings

(100.7m)(124.5m)(179.3m)(176.5m)(189.8m)(214.5m)

Total Equity

30.3m18.0m(2.6m)3.9m3.6m38.2m

Financial Leverage

1.3 x1.7 x-14.2 x4.8 x3.7 x1.3 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

62.9m48.5m23.9m1.3m1.3m3.9m13.5m11.0m32.3m28.4m23.4m19.6m20.7m16.8m12.8m8.6m59.3m54.0m39.7m

Prepaid Expenses

2.0m1.8m1.4m5.7m5.4m6.4m6.4m5.4m3.9m3.0m2.5m1.7m948.0k825.0k712.0k349.0k903.0k633.0k446.0k

Current Assets

73.6m60.9m46.9m23.1m18.6m17.5m23.2m20.4m39.4m34.8m28.8m22.5m21.7m17.7m13.7m9.0m60.3m54.7m40.2m

PP&E

1.6m1.5m1.8m1.7m1.6m1.5m1.3m1.2m1.1m935.0k845.0k755.0k576.0k488.0k401.0k270.0k228.0k198.0k140.0k

Total Assets

75.2m62.4m49.2m31.2m26.3m22.8m25.8m22.4m40.9m35.9m29.8m23.6m24.8m20.6m16.6m11.6m62.7m57.0m42.2m

Accounts Payable

659.0k966.0k934.0k641.0k2.0m2.2m3.9m2.8m2.8m4.6m4.1m4.4m2.6m2.8m2.3m2.2m2.8m3.8m3.8m

Short-term debt

669.0k680.0k692.0k716.0k

Current Liabilities

12.8m11.2m8.6m7.3m6.2m4.8m6.1m5.5m6.4m8.4m9.0m9.1m7.3m6.7m7.0m6.8m6.6m9.0m8.1m

Long-term debt

1.9m1.7m1.8m1.5m1.3m1.1m773.0k

Total Debt

1.9m1.7m1.8m2.2m2.0m1.8m1.5m

Total Liabilities

12.8m11.2m8.6m7.3m6.2m4.8m25.0m23.1m25.2m33.7m37.6m19.7m14.5m9.1m9.3m9.4m9.3m11.2m9.1m

Common Stock

129.0k129.0k130.0k135.0k139.0k145.0k330.0k352.0k550.0k574.0k578.0k587.0k689.0k689.0k689.0k49.0k95.0k95.0k95.0k

Preferred Stock

Additional Paid-in Capital

129.4m129.8m130.2m131.5m132.8m134.9m144.1m146.4m170.3m176.9m178.3m178.9m186.9m192.2m192.3m196.8m251.9m252.3m253.0m

Retained Earnings

(67.1m)(78.7m)(89.9m)(107.7m)(112.9m)(117.1m)(143.6m)(147.6m)(155.2m)(175.2m)(186.7m)(175.6m)(177.3m)(181.4m)(185.7m)(194.7m)(198.6m)(206.5m)(220.0m)

Total Equity

62.4m51.2m40.5m23.9m20.1m18.0m800.0k(787.0k)15.7m2.2m(7.8m)3.9m10.3m11.5m7.3m2.1m53.4m45.9m33.1m

Financial Leverage

1.2 x1.2 x1.2 x1.3 x1.3 x1.3 x32.2 x-28.4 x2.6 x16.2 x-3.8 x6 x2.4 x1.8 x2.3 x5.4 x1.2 x1.2 x1.3 x

Bellerophon Therapeutics Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(46.5m)(23.8m)(54.8m)2.8m(13.3m)(24.7m)

Depreciation and Amortization

373.0k362.0k348.0k147.0k

Cash From Operating Activities

(46.3m)(17.2m)(15.7m)(15.5m)(12.9m)(19.9m)

Purchases of PP&E

(458.0k)(22.0k)

Cash From Investing Activities

(18.3m)12.2m2.6m3.0m

Cash From Financing Activities

54.0m13.2m27.8m166.0k6.2m57.6m

Net Change in Cash

(10.6m)8.2m14.6m(12.3m)(6.8m)37.7m

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(12.9m)(24.5m)(35.6m)(7.1m)(12.2m)(16.4m)(19.1m)(23.1m)(30.7m)4.1m(7.4m)3.7m(795.0k)(4.9m)(9.2m)(5.0m)(8.8m)(16.7m)(5.5m)

Depreciation and Amortization

92.0k183.0k273.0k104.0k202.0k301.0k99.0k192.0k283.0k91.0k181.0k271.0k88.0k176.0k263.0k46.0k88.0k118.0k29.0k

Accounts Payable

(796.0k)(552.0k)1.3m2.0m2.0m(727.0k)(1.2m)(987.0k)(830.0k)(1.3m)1.3m

Cash From Operating Activities

(8.8m)(18.0m)(29.0m)(6.7m)(11.5m)(14.8m)(3.7m)(8.2m)(11.2m)(444.0k)(6.1m)(11.4m)(2.3m)(6.1m)(10.0m)(4.3m)(8.6m)(13.5m)(7.9m)

Purchases of PP&E

(424.0k)(22.0k)(22.0k)(22.0k)

Cash From Investing Activities

(4.2m)(17.8m)1.7m5.9m10.5m2.5m1.7m2.4m502.0k2.0m

Cash From Financing Activities

54.9m53.9m53.9m651.0k1.9m285.0k3.0m26.7m(28.0k)141.0k166.0k6.4m6.2m6.2m3.1m58.0m57.6m

Net Change in Cash

46.1m31.7m7.1m(5.0m)(5.0m)(2.3m)(914.0k)(3.5m)17.8m(472.0k)(5.4m)(9.3m)4.0m154.0k(3.8m)(1.3m)49.4m44.1m(7.9m)

Bellerophon Therapeutics Ratios

USDQ1, 2015

Financial Leverage

1.2 x
View Bellerophon Therapeutics profile

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Learn more